Acutus Medical

Acutus Medical, Inc. engages in the development of medical devices and electrophy equipment. It creates electrophysiological mapping systems for the treatment of cardiac arrhythmias, such as atrial fibrillation, and ventricular tachycardia. The company was founded by Randell L. Werneth and Christoph Scharf in 2011 and is headquartered in Carlsbad, CA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acutus's cardiac mapping technology is an enormous leap in diagnostic capabilities for doctors performing ablation to treat AF and other arrhythmias. The AcQMap system dramatically increases the success rate of ablation procedures, and improves their safety and efficiency.

Acutus Medical, Inc.: Paradigm-Shifting Technology At A Shocking Price

CARLSBAD, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”) today announced the pricing of its underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares of common stock are being offered by Acutus. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Acutus, are expected to be $77.0 million. The offering is expected to close on July 19, 2021, subject to the satisfaction of customary closing conditions. In addition, Acutus has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of Acutus' common stock at the price to the public, less underwriting discounts and commissions.

Acutus Medical, Inc. Announces Pricing of Public Offering of Common Stock

CARLSBAD, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today announced it has commenced an underwritten public offering of 5,500,000 shares of its common stock. All of the shares of common stock are being offered by Acutus. In addition, Acutus expects to grant the underwriters a 30-day option to purchase up to an additional 825,000 shares of its common stock in the offering.

Acutus Medical, Inc. Announces Proposed Public Offering of Common Stock

CARLSBAD, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported preliminary unaudited results for the second quarter of 2021.

Acutus Medical Reports Preliminary Unaudited Second Quarter 2021 Financial Results

The FDA has signed off Investigational Device Exemption (IDE) AcQBlate AF trial for Acutus Medical Inc's (NASDAQ: AFIB) AcQBlate Force Sensing Ablation Catheter and System. The trial is expected to enroll 350 subjects and evaluate the system's safety and efficacy in the treatment of both paroxysmal and persistent atrial fibrillation.

Acutus Medical Receives Green Signal From FDA To Start AcQBlate Atrial Fibrillation Trial

CARLSBAD, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (“AF”) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System. In the US, AF ablation procedures total approximately 190,000 per year and are projected to reach 375,000 annually by 20251. This trial is expected to enroll 350 subjects in leading centers globally and will evaluate the safety and efficacy of the system in the treatment of both paroxysmal and persistent atrial fibrillation.

Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System

CARLSBAD, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will participate at the 41st Annual William Blair Growth Stock Conference on Thursday, June 3, 2021 at 12:20 p.m. Eastern Time.

Acutus Medical to Present at the 41st Annual William Blair Growth Stock Conference

Acutus Medical, Inc. (AFIB) CEO Vince Burgess on Q1 2021 Results - Earnings Call Transcript

CARLSBAD, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2021.

Acutus Medical Reports First Quarter 2021 Financial Results

CARLSBAD, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the first quarter of 2021 on Wednesday, May 12, 2021. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce First Quarter 2021 Financial Results

CARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will participate at the following upcoming investor conferences:

Acutus Medical to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced initial US enrollments in the company's AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial. This trial is expected to enroll up to 150 subjects in leading centers globally and will evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of Right Atrial Typical Flutter. In the US, Right Atrial Typical Flutter ablation procedures currently account for approximately 30% of cardiac ablations and are expected to reach 200,000 annually by 20251.

Acutus Medical Initiates First IDE Therapy Trial with the AcQBlate® FORCE Sensing Ablation System

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 p.m. Eastern Time.

Acutus Medical to Present at the 20ᵗʰ Annual Needham Virtual Healthcare Conference

CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2020.

Acutus Medical Reports Fourth Quarter and Full Year 2020 Financial Results

CARLSBAD, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the fourth quarter and full year of 2020 on Thursday, March 18, 2021. In conjunction with the release, Acutus will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Acutus Medical to Announce Fourth Quarter and Full Year 2020 Financial Results

Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System

Acutus Medical Receives Vizient Innovative Technology Contract

CARLSBAD, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB) today announced the appointment of David Roman as the company's Chief Financial Officer, effective March 1, 2021. In addition, Daniella Cramp has joined the Company's board of directors, effective February 3, 2021.

Acutus Medical, Inc. Appoints New Chief Financial Officer and New Board Member

CARLSBAD, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021 at 2:00 p.m. Eastern Time.

Acutus Medical to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported preliminary unaudited revenue results for the quarter and full year ended December 31, 2020.

Acutus Medical Reports Preliminary, Unaudited Fourth Quarter and Full Year 2020 Results

CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that its management will present at the upcoming J.P. Morgan 39th Annual Healthcare Conference on Wednesday, January 13, 2021 at 10:00 a.m. Eastern Time.

News for Acutus Medical Stock (AFIB)